DNA polymerase etaGenealiases: RAD30 · RAD30A · XP-V · XPV
Q-omics provides the consensus-scored POLH profile across patient tissues and cancer cell-line models. POLH expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, POLH is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, POLH RNA expression shows 20,710 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where POLH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POLH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POLH survival associations across molecular data types. POLH RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POLH RNA expression–survival associations across cancer types. High POLH expression shows unfavorable associations in ACC, KICH and LGG, but favorable associations in KIRC, HNSC and THYM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for POLH RNA expression.
This table summarizes POLH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for POLH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POLH shows lower tumor expression in KICH and higher tumor expression in KIRC, KIRP, LIHC, BRCA and CHOL. The KIRC box plot shows higher POLH RNA expression in tumor versus normal tissue (log2 FC = +0.980, t-test p < 0.001).
This table shows molecular features associated with POLH in patient tissues and cancer cell lines. In patient samples, POLH shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, POLH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
